Ke hōʻike ʻia nā Pepa i nā Vectors Vendor: Pehea e heluhelu ai i ka Reagent Citations (Nānā Hiʻohiʻona: GenScript pcDNA3 ma MDM2 Research)

Pane wikiwiki

Master systematic evaluation methods for supplier citations in academic literature, alongside independent quality verification of carrier vectors and synthetic peptides for MDM2 target research. Conduct dual identification via Sanger sequencing and NGS for plasmids, paired with HPLC-MS characterization for peptide purity and structural validation, eliminating reagent quality risks to guarantee reliable reproducibility of MDM2 biological functional experiments.

Ke hōʻike ʻia nā Pepa i nā Vectors Vendor: Pehea e heluhelu ai i ka Reagent Citations (Nānā Hiʻohiʻona: GenScript pcDNA3 ma MDM2 Research)

Ke hōʻike ʻia nā Pepa i nā Vectors Vendor: Pehea e heluhelu ai i ka Reagent Citations

Ke nānā nei nā mea noiʻi nui a me nā ʻepekema noiʻi koʻikoʻi i nā palapala i paʻi hou ʻia ma ka oncology a i ʻole ka cell biology, Hoʻohana pinepine ʻia nā huaʻōlelo mea kūʻai aku ma ke ʻano he hōʻailona hōʻoia o ka ʻae. ʻO ka ʻike ʻana i kahi vector hōʻike mammalian kalepa a i ʻole peptide maʻamau i ʻōlelo ʻia ma waena o iwakālua mau pepa i loiloi ʻia e nā hoa e hana i kahi manaʻo o ka hilinaʻi.. Inā kūʻai mau nā hale hana kūʻokoʻa he nui i kahi GenScript pcDNA3 vector kikoʻī a i ʻole kahi peptide synthetic kalepa e aʻo ai i ka hōʻailona MDM2-p53., He mea kūpono ke kauoha i ka helu helu helu like a hoʻomau pololei i ka hoʻokō bench.

Eia naʻe, ʻO ka mālama ʻana i nā huaʻōlelo mea kūʻai aku ma ke ʻano he mea koho no ka maikaʻi o ka batch empirical kekahi o nā kumu maʻamau o ka ʻikepili ʻikepili hiki ʻole ke hoʻololi ʻia.. Hoʻohana ʻia nā huaʻōlelo i loko o nā puke moʻolelo i nānā ʻia e nā hoa, ʻaʻole nui ke kino, kemika, a i ʻole hōʻoia hana. Loaʻa nā iwi kuamoʻo plasmid pāʻoihana i ka hoʻoponopono hou ʻana o ka mea kūʻai aku, ʻO ka hele ʻana i nā ʻano mea hoʻokipa e hoʻolauna i nā subpopulations ʻano liʻiliʻi, a hiki i nā mea hoʻolaha hōʻike i alakaʻi ʻia e nā mea hoʻolaha viral hiki ke hana me ka ʻike ʻole ʻia ma muli o ke ʻano genetic cellular.

Pono e aʻo i ka heluhelu ʻana i nā huaʻōlelo puke me ke koʻikoʻi a me ka hoʻokō ʻana i kahi mea kūʻokoʻa, mana maikaʻi orthogonal (QC) protocol ma mua o ka hoʻohana ʻana i kekahi reagent i hoʻohana ʻia.


Kūʻai Kūʻai Kūʻai Kūʻai vs. Nā Kākoʻo hanana: Hoʻopau i nā hōʻailona hōʻoiaʻiʻo ʻole

E loiloi pono i nā mea i hoʻokumu ʻia i ka palapala, Pono nā laboratories e hoʻokaʻawale i waena o nā hōʻailona kālepa like ʻole. Ma ka hoʻopuka ʻepekema, haʻi aku ka mea kūʻai aku, nā huaʻōlelo waihona, a me nā kākoʻo hanana hanana i nā hana hoʻomalu a hoʻolaha kūʻokoʻa, akā, ʻaʻohe o lākou e hōʻoiaʻiʻo e hana like ka hailona hou mai kahi mea kūʻai aku i kāu ʻike.

Haʻi palapala / RRID → Moʻolelo Hoʻohana Moʻolelo (Kahi i kūʻai ʻia ai)

Kākoʻo Kūʻai Kūʻai → Hōʻailona Kūʻai Kūʻai (ʻIke ʻia ka brand)

QC Orthogonal & CoA → Hōʻoia Manaʻo (ʻIkepili kikoʻī nui & ka maemae)

Nā Huaʻōlelo Literature and Research Resources Identifiers (RRIDs)

Ke hoʻopaʻa inoa ka pepa i kahi helu helu a i ʻole Research Resource Identifier (MAKEMAKE AU), hoʻokumu ia i ka traceability no ka ʻikepili i paʻi ʻia. Hoʻoikaika nā hana ʻōlelo maʻamau i ka hōʻoia a me ka reproducibility empirical ma ka ʻae ʻana i ka poʻe heluhelu e hahai i nā kumu waiwai ma nā haʻawina., e like me ka mea i hoikeia ma Nā alakaʻi hoʻopuka NIH e pili ana i ka hōʻoia ʻana a me nā ʻikepili ʻikepili.

Hoʻohui ʻia nā papa hana kikokikona e like me CiteAb i kēia mau huaʻōlelo e ana i ka hoʻohana ʻana i ka mākeke a me nā ʻano hoʻohana, hāʻawi i ka ʻike koʻikoʻi i ka noho ʻana o ka mea kūʻai aku, e like me ka mea i hoakakaia ma ʻO CiteAb's life science product citation analysis. Ke kuhikuhi nei i nā helu helu helu huahana, helu nui, a me nā RRID e hōʻoia i hiki i nā hoa ʻepekema ke ʻike i ka mea i lalo, e like me ka mea i hoakakaia ma Ke alakaʻi a StressMarq ma nā huaʻōlelo huahana RRID.

Eia naʻe, ʻO kahi puke moʻolelo i hoʻopaʻa ʻia i ka mea a kahi hui noiʻi mua i kūʻai ai-ʻaʻole ia e hōʻoia i ka hōʻoia kūʻokoʻa o ka reagent ma mua o ka paʻi ʻia ʻana o kā lākou mau hoʻokolohua..

Ki Takeaway: Ua hōʻoia ʻia kahi manaʻo i nānā ʻia e nā hoa i hoʻohana ʻia kahi kumu kūʻai kūikawā ma kahi noiʻi i paʻi ʻia, akā ʻaʻole ia e pani i ke kino kikoʻī nui, kaʻina, a i ʻole ka hōʻoia hana ma kāu keʻena hana ponoʻī.

Nā Kūʻai Kūʻai Kūʻai Kūʻai a me ka ʻike maka

Nā kākoʻo hanana—e like me nā hale kūʻai ma nā symposiums nui, nā papa hana ʻenehana kākoʻo, a i ʻole nā ​​hāʻawi huakaʻi ʻepekema—e hana wale ʻia ma ke ʻano he hōʻailona ʻike ʻike kalepa. Hōʻike ka kākoʻo i ka hiki ke kūʻai aku o ka mea kūʻai aku, ʻaʻole ka maʻemaʻe analytical a i ʻole ka pono hana o kā lākou mau mea hoʻohui ola.

ʻO ka hilinaʻi ʻana i ka kaulana o ka mea kūʻai aku a i ʻole nā ​​​​huaʻōlelo puke ma ke ʻano he pani no ka hoʻokele maikaʻi o loko e hoʻokumu i ka pilikia koʻikoʻi., ma nā ala hoʻoponopono koʻikoʻi e like me ka hōʻailona MDM2/p53.


Nānā Hiʻohiʻona: Hana ʻia ʻo GenScript pcDNA3 Expression ma MDM2/p53 Signaling Research

No ka hoʻomaopopo ʻana pehea e hiki ai i nā vector i kuhikuhi ʻia i ka palapala ke hoʻolauna i ka ʻokoʻa hoʻokolohua, e noʻonoʻo i ka hoʻohana ʻana o GenScript pcDNA3 i kūkulu ʻia i ka noiʻi MDM2.

ʻIole pālua minuke 2 (MDM2) he E3 ubiquitin ligase e hana ma ke ʻano he mea hoʻoponopono maikaʻi ʻole o ka p53 tumor suppressor protein.. I nā ʻōnaehana p53 ʻano hihiu, Hoʻopili ʻo MDM2 i ka N-terminal transactivation domain o p53, ke kuhikuhi nei iā ia no ka hoʻohaʻahaʻa ʻana i ka proteasomal i loko o kahi loop manaʻo maikaʻi ʻole, e like me ka mea kiko'ī ma he loiloi piha i kēia manawa Pharmaceutical Design. No ka mea hiki i ka overexpression MDM2 ke hoʻopau i ka hana p53 me ka ʻole o ka hoʻololi ʻana o ka gene, huli pinepine nā mea noiʻi i nā plasmids MDM2 recombinant e loiloi i ka hopu ʻana o ka pōʻai cell, apoptosis, a i ʻole nā ​​mea hoʻopaneʻe MDM2-p53 liʻiliʻi.

pcDNA3 Expression Vector Backbone CMV Promoter → Epitope Tag → MDM2 Insert → BGH PolyA (Hoʻopiʻi ʻia e p53) (Hiki ke hoʻololi i ka E3) (RING Domain) (Paʻa palapala)

ʻO nā Plasmids e like me pcDNA3 MDM2 WT ua hoʻopaʻa nui ʻia i loko o nā waihona hoʻonaʻauao, komo ka Addgene pcDNA3 MDM2 WT waihona waihona, a hoʻohui hou ʻia a hoʻololi ʻia e nā mea kūʻai aku e like me GenScript. ʻO ka iwi kuamoʻo vector pcDNA3 (5.4 kb) hoʻohana i ka cytomegalovirus kanaka (CMV) mea hoʻolaha koke no ka hōʻike mammalian kiʻekiʻe, he kumu SV40 no ka replication episomal ma SV40 nui T-antigen e hōʻike ana i nā pūnana hoʻokipa (e like me HEK293T), a me kahi māka koho neomycin/G418.

Mea hana hoʻokolohua 1: Hoʻopiʻi ʻo CMV Promoter e ka Wild-Type p53

ʻO kahi pitfall nui i nā haʻawina hōʻike MDM2 e pili ana i ka hoʻoponopono hoʻolaha. ʻOiai ua mālama ʻia ka mea hoʻolaha CMV ma pcDNA3 ma ke ʻano he mea hoʻolaha constitutive ikaika, Hōʻike nā haʻawina empirical i ka hoʻopaʻa ʻia ʻana o ka hana hoʻolaha CMV e nā kiʻekiʻe p53 kiʻekiʻe., e like me ka hoike ana ma he haʻawina i paʻi ʻia ma ka Journal of Biological Chemistry. ʻO Rasa Research Peptides mea hoʻolako

Ke hoʻololi ka poʻe noiʻi i ka pcDNA3-MDM2 i loko o nā pūnaewele me ka hōʻailona p53 paʻa, ʻO ka piʻi ʻana o nā pae p53 e kāohi i ka mea hoʻolaha CMV, ka hopena i ka laina ole, hōʻike MDM2 hoʻopaʻa ponoʻī. Inā manaʻo kekahi pūʻulu noiʻi i ka hana hoʻolaha mau e pili ana i nā ʻōlelo palapala, Hiki ke hoʻololi i ka nui o ka protein MDM2 no ka hoʻāʻo ʻana i ka pono o ka hui ʻana a i ʻole ka hoʻohaʻahaʻa ʻana ma hope o ka unuhi ʻana ma mua o ka hoʻopau ʻana i ka mea hoʻolaha..

Noke hihia Bench (Hoʻololi ʻo MOL i ke Keʻena Mana Mana Mea): I ka hoʻopaʻa ʻana o ka orthogonal cross-validation o ka palapala-sourced pcDNA3 plasmid constructs, ʻO ke kaʻina ʻana o Sanger ʻelua ma waena o nā hui hoʻokomo-hoʻokomo i ʻike ʻia i nā ʻano like ʻole hoʻokahi-nucleotide i palapala ʻia. (SNV) i loko o ka ʻāpana CMV koke-hoʻolaha mua. ʻO kēia mau kahe liʻiliʻi liʻiliʻi i hopena i kahi ~ 35% ka hōʻemi ʻana i ka hana hoʻolaha baseline i nā hiʻohiʻona cell wild-type i hoʻohālikelike ʻia me nā palapala kuhikuhi NCBI canonical - e hōʻike ana i ke kumu e koi ʻia ai ka hōʻoia ʻana o ka genetic sequence ma mua o ka hoʻokō ʻana i nā hoʻokolohua cellular lalo..

Mea hana hoʻokolohua 2: Hoʻololi ʻia ʻo Epitope a me RING-Finger Domain

E hahai i ka recombinant MDM2, Hoʻopili pinepine nā vectors kalepa i nā hōʻailona epitope N-terminal a i ʻole C-terminal (e like me Myc, HAE, a i ʻole GFP). Ke hilinaʻi nei ʻo MDM2 i kāna kikowaena C-terminal RING-finger domain no ka hana E3 ubiquitin ligase a me ka homodimerization. Nā Peptides Stapled

Inā hoʻololi ka mea kūʻai pāʻoihana i ka hui cloning a i ʻole i hoʻokomo ʻia kahi hōʻailona ma kahi kokoke i ka RING-finger domain me ka ʻole o ka hōʻoia ʻana o ke kūkulu ʻana., Hiki ke hōʻike ʻia ka protein fusion i hōʻemi ʻia i ka hana ligase E3 a i ʻole ka hoʻololi ʻana i ke kiko o ka substrate. Pono ka hoʻonohonoho ʻana o Sanger o nā hui hoʻokomo a me ka spectrometry mass orthogonal e hōʻoia ʻaʻole i hoʻopau ka tag i ka hoʻopili ʻana o ka waihona..


ʻO nā pilikia huna o nā mea hoʻohana i hoʻohana ʻia i ka palapala: Kaʻa Kaʻa, Hoʻopilikia i ka Tag, a me ka hoʻololi ʻana o ka hui

ʻO ka hoʻokomo ʻana i nā reagents i hōʻike ʻia i ka palapala me ka ʻole o ka hōʻoia ʻana e hoʻolauna i ʻekolu mau ʻano hana hemahema ʻenehana:

  1. Nā ʻano hoʻololi ʻole ʻia a me ka Sequence Drift: Hiki i nā plasmid i hoʻolaha ʻia ma waena o nā maʻi bacterial host ke hōʻiliʻili i nā hoʻololi kiko, hookomo, a i ʻole nā ​​mea transposon. ʻO ka hele ʻana i ka plasmid preps me ka ʻole o ka hoʻopili ʻana i nā palena hoʻokomo hiki ke hoʻololi i ka ikaika o ka mea hoʻolaha a i ʻole e hoʻokomo i nā hoʻololi leo / missense i ka frame coding..
  2. Peptide a me Reagent haumia: I ka peptide synthesis (e like me MDM2-binding helical peptides a i ʻole p53-derived tracer peptides), Hiki i nā mea hoʻolako pāʻoihana ke hāʻawi i nā mea i loaʻa nā kaʻina holoi holoi ʻia ((n-1) a i ʻole (n-2) isomers) ina aole lawa ka hoomaemae ana. Hiki i nā peptides synthetic i hoʻomaʻemaʻe ʻole ke kumu i nā kinetics hoʻopaʻa maikaʻi ʻole i ka resonance plasmon surface (SPR) a i ʻole ka polarization fluorescence (FP) nā hoʻokolohua.
  3. ʻO nā ʻokoʻa CoA a me ka Lot Insibility: Nā palapala hōʻoia o ka ʻike (CoAs) Hāʻawi ʻia e nā mea hoʻolako e hōʻike paha i ka hoʻāʻo ʻana o ka pūʻulu mōʻaukala ma mua o ka hue kikoʻī i hāʻawi ʻia i kāu keʻena keʻena. Me ka hōʻoia ʻole ʻana i ka traceability a me ka hoʻāʻo ʻana i ke kūpaʻa mālama, Hiki i nā ʻokoʻa hoʻomaʻemaʻe nui-a-lot ke hoʻololi i ka reproducibility quantitative.

No ke kōkua: Mai noʻonoʻo e hōʻike ana kahi palapala hōʻoia kālepa i ke kūlana kino o kahi reagent ma hope o ka lawe ʻana. E holo mau i ka ʻike kūloko a me ka hoʻomaʻemaʻe i ka loaʻa ʻana.


ʻO ka 3-Stage Independent Validation Protocol for Literature-Sourced Reagents

No ka pale ʻana i nā papahana noiʻi mai nā mea hana reagent i hōʻoia ʻole ʻia, pono e hoʻokumu nā laboratories i kahi standardized, ʻekolu-pae orthogonal validation workflow.

Ke kahua 1: Hoʻoponopono Lineage → Pae 2: Kaʻina & QC kino → Pae 3: Nā Mana Hana

(KoA & MAKEMAKE au e nana) (Mea mele/NGS & RP-HPLC/MS) (p53-null & ʻO nā hoʻokolohua Proteasome)

Ke kahua 1: Lineage Audit and Lot Traceability

Ma mua o ka wehe ʻana a i ʻole ka hoʻololi ʻana i kahi kūkulu vector hou a i ʻole peptide synthetic, hōʻoia i kāna palapala piha:

  • Hoʻopaʻa ʻikepili ʻikepili: E kākau i ka inoa o ka mea kūʻai aku, helu helu helu pololei, ID clone, helu pūʻulu/nui, a me RRID.
  • Hoʻoponopono i ka palapala ʻāina kūʻai aku a me CoA: Hoʻohālikelike i ka palapala plasmid i hoʻolako ʻia e ka mea kūʻai aku a i ʻole

    No Peptides E hoʻokumu i ka Lineage Freezer: No nā plasmids, e hahai i ka maʻi bacterial host, ke koho ʻana i nā lāʻau antibiotic, a me ka helu pauku mai ka hoololi mua.

    ke koho ʻana i nā lāʻau antibiotic, a me ka helu pauku mai ka hoololi mua.

Ke kahua 2: ʻO ke Kaʻina Orthogonal a me ke ʻano o ke kino

Pono e mālama ʻia ka hōʻoia kino a me ka genetic ma mua o ka holo ʻana i nā hoʻokolohua biological:

  • Sanger Sequencing: Hana i ka hoʻokaʻina Sanger bidirectional ma waena o nā hui hoʻokomo hoʻolaha, hōʻailona epitope, a me nā paena hoʻololi ʻenehana.
  • Ke Kaʻina Hana Hana Hou (NGS): No ka paʻakikī, lōʻihi, a i ʻole multi-cistronic vectors, hoʻohana i ke kaʻina heluhelu lōʻihi (e like me Oxford Nanopore a i ʻole PacBio) e ʻike i nā quasispecies haʻahaʻa haʻahaʻa a i ʻole nā ​​​​hoʻonohonoho hou ʻana o ka iwi kuamoʻo i hala ʻole ke kaʻina hana Sanger..
  • RP-HPLC a me Mass Spectrometry (MS) no nā Peptides: Ke hoʻohana nei i nā reagents peptide synthetic, e hoʻopili i ka hāpana me ka hoʻohana analytical C18 Reverse-Phase HPLC (0.1% TFA ma H₂O/ACN gradient) e hōʻoia i ka hopena kiʻekiʻe (Rₛ ≥ 1.5) a me ka maemae (≥ 98%). E hōʻoia i ke kaumaha molekala me ka High-Resolution Electrospray Ionization Mass Spectrometry (ESI-MS) me ka hapa nui ma lalo 5 ppm.

No nā laboratories e ʻimi nei i ka synthesis maʻamau a me ka hōʻoia, ka hoʻohana ʻana i kahi kahua hana peptide synthesis maʻamau kākoʻo ʻia e ka laulā analytical HPLC a me nā lawelawe hoʻāʻo nui spectrometry e hōʻoia i kēlā me kēia kaʻina i hāʻawi ʻia i ka hōʻailona koʻikoʻi ma mua o ka hoʻohana ʻana.

Ke kahua 3: Nā Mana Ala Hana Hana

ʻO ka hōʻoia ʻana o ke olaola e hōʻoia ana e hana pololei ana ka protein i hōʻike ʻia a i ʻole peptide synthesized i loko o ka pōʻaiapili kelepona.:

  • Hōʻikeʻike a me ka nui: Hana i ka Western blot a i ʻole immunoprecipitation analysis e hōʻoia i ke kūkulu ʻana i hōʻike ʻia e kūlike me ke kaumaha molekala i wānana ʻia me ka ʻole o nā huahana degradation i manaʻo ʻole ʻia..
  • Nā Mana Pūnaewele Genetic Background: I ka loiloi ʻana i nā kūkulu MDM2, hoʻokomo i nā laina pūnaewele p53-null (e like me Saos-2 a i ʻole H1299) me nā laina p53-wildtype (e like me MCF-7 a i ʻole U2OS) e hoʻokaʻawale i nā mea ʻawaʻawa pili i ka p53 mai nā hopena vector off-target.
  • ʻO nā hōʻike hōʻemi Proteasome: E mālama i nā pūnaewele i hoʻololi ʻia me nā mea hoʻopaneʻe proteasome (e like me MG132) e hōʻoia e hiki ke hoʻopakele ʻia ka MDM2-mediated p53 degradation, hoʻokumu i ka hana ligase E3 hana.

Pākuʻi Papa: Ka Papa Hoʻopaʻa Laboratory no ka Reagent Validation and Replication

Hāʻawi ka papa helu loiloi ma lalo nei i kahi i hoʻonohonoho ʻia no

Hōʻoia Hale Hana Hui Peptide hilinai Ke kahua

nā vectors a me nā peptide reagents maʻamau ma mua o ka hoʻokō hoʻokolohua:

Ka Papa Hooia ʻĀpana / Hoao Koina ʻae Kāohi ʻia ʻo Primary Artifact
Ke kahua 1: Kuauhau Lot Traceability & Hooia CoA Helu hui like

Liraglutide Api Mea Hoʻolako Mea Hana 100% ka ʻike kikoʻī ma waena o ka mea hoʻolaha, nā hōʻailona, a hookomo i na palena

>

Ke kūʻai ʻana i nā isoform plasmid kūpono ʻole a i ʻole nā ​​​​mea kikoʻī i hoʻololi ʻia

Ke kahua 2: Kaʻina Sanger / ʻO ka hoʻonohonoho ʻana o NGS Junction Sequencing 100% ka ʻike kikoʻī ma waena o ka mea hoʻolaha, nā hōʻailona, a hookomo i na palena Nā hoʻololi hoʻololi ʻana, hoʻololi kiko, a me ka holoi ʻana i ka hui
Ke kahua 2: QC kino RP-HPLC Hoʻomaʻemaʻe ʻana Kiʻekiʻe chromatographic ʻoi hoʻokahi, maemae ≥ 98%, Rₛ ≥ 1.5 ʻOki ʻia nā kaʻina holoi holoi (n-1) a me nā huahana ʻaoʻao synthesis
Ke kahua 2: Nui QC ESI-MS hoʻoholo kiʻekiʻe Hoʻohuihui Peptide Monoisotopic mass pololei i loko < 5 ppm o ka nuipaʻa theoretical ʻO ka hoʻololi ʻana i ka waikawa amino kūpono ʻole a i ʻole ka deprotection piha ʻole
Ke kahua 3: Hana pono Western Blot & Hōʻoia Hōʻike Kaumaha molekalale pololei; ʻaʻohe huahana cleavage i manaʻo ʻole ʻia Ke kuhi hewa ʻana i ka protein, hoʻohaʻahaʻa wikiwiki, a i ʻole ka hāʻule ʻana o ka ʻōlelo leo leo
Ke kahua 3: Alanui Isogenic & Null Cell Controls Hoʻomaʻemaʻe i ka ʻokoʻa hana ma ka p53-wildtype vs. p53-null cell Hoʻopili wahaheʻe o nā mea ʻawaʻawa vector i ka hōʻailona ala ala

Ka mālama ʻana i ka hana hou ʻana o ka hoʻokolohua ma ka Custom Vector a me Peptide R&ʻO D

Hāʻawi nā huaʻōlelo palapala i kahi hoʻomaka no ke koho reagent, akā ʻaʻole hiki iā lākou ke hoʻololi i ka mana o loko. Ke ulu nei ka noiʻi biomedical i ka nānā ʻana i ka reproducibility data, nā laboratories e hōʻoia kūʻokoʻa i kēlā me kēia vector construct a me peptide batch e pale i kā lākou hoʻopukapuka waihona, pale i nā hola noiʻi makehewa, a e hōʻoia i ka paʻa o nā hopena i paʻi ʻia.

Ke ʻimi nei i nā mea kūikawā a i ʻole ka hoʻonui ʻana i nā kaʻina maʻamau, e hana pū ana me kekahi hoa kālailai e hana ana i loko Papa 100 nā lako lumi hoʻomaʻemaʻe sterile e hōʻoia i ka hoʻopau ʻia ʻana o nā endotoxins kaiapuni mai ka hana ʻana. Eia kekahi, leveraging nā hoʻonā peptide CRO kūikawā hiki i nā hui noiʻi ke loaʻa i nā mea i paʻi ʻia piha—i kākoʻo ʻia e kēlā me kēia HPLC chromatograms, ESI-MS kikoo, a me nā CoA kikoʻī he nui-ma mua o ka hoʻomaka ʻana i nā hoʻāʻo koʻikoʻi cell.

Ma ka hoʻohui ʻana i ka loiloi palapala koʻikoʻi me kahi protocol validation 3-pae koʻikoʻi, Hiki i nā keʻena noiʻi ke hoʻohana me ka hilinaʻi i nā mea hana i kākau ʻia i ka palapala ʻoiai e mālama ana i ka pono a me ka hana hou ʻana o kā lākou huahana ʻepekema..


Nā ʻanuʻu aʻe no R&D Nā Hui

Pono ʻoe i kahi hiʻohiʻona kūʻokoʻa a i ʻole synthesis peptide maʻemaʻe kiʻekiʻe no kāu pipeline noiʻi? E kelepona i nā loea analytical ma MOL Changes e noi i ka loiloi loea, nānā i nā ʻāpana hoʻāʻo analytical, a i ʻole e ʻimi i nā hoʻonā synthesis maʻamau i kūpono i kāu mau koi hoʻokolohua.


E pili ana i nā mea loiloi ʻepekema

Ua kākau a loiloi ʻia kēia alakaʻi ʻenehana e ka Hoʻololi ʻo MOL i ka Papa Kūkākūkā ʻepekema & Hui noiʻi—he hui hui o na peptide chemists kahiko, nā mea ola molekala, a me nā loea QC analytical. Ke hana nei i loko o ka Papa 100 nā lako lumi hoʻomaʻemaʻe sterile, ʻO ka hui MOL Changes kūikawā i ka hoʻolālā peptide sequence maʻamau, microbial/solid-phase synthesis, a me ka hōʻoia analytical hailona koʻikoʻi (RP-HPLC, ESI-MS, a me ka ho'āʻo sterility) e kākoʻo i ka noiʻi ʻepekema reproducible.

Jinling Liu

Jinling Liu

Kaʻina hana R&D a me ka Mea Hana Hana Kaʻike kumu: Hoʻonui kaʻina hana, kemika ʻōmaʻomaʻo, hoʻomaikaʻi maikaʻi, Hoʻokō ka hana GMP.

Pilikino: He loea ʻo Jinling Liu i ka unuhi ʻana o nā lāʻau peptide mai ka pālākiō keʻena (pae milligram) i ka hana pāʻoihana (pae kilokani). Ua kūpaʻa ʻo ia i ka hōʻemi nui ʻana i nā kumukūʻai hana peptide a me ka hōʻemi ʻana i ka pollution kaiapuni ma o ka hoʻonui ʻana i nā kūlana cleavage., ka hoʻomaikaʻi ʻana i nā lakio o nā condensation reagents, a me ka hoʻolauna ʻana i ka ʻenehana synthesis kahe mau. Ua alakaʻi ʻo ia i ka optimization o nā papahana peptide he nui, ka loaʻa ʻana o ke kumu kūʻai haʻahaʻa, hoʻomaʻemaʻe kiʻekiʻe ma ka pālākiō 100-kilogram.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana